Novo Nordisk's Amycretin: Pioneering Weight Loss Revolution
Novo Nordisk's experimental drug amycretin shows promising results in early trials, aiding significant weight loss in overweight and obese individuals. The drug, mimicking gut and pancreatic hormones, led to weight reductions up to 24.3%. The company plans further studies for 2026, targeting regulatory approval thereafter.
Novo Nordisk has announced promising results from its early-stage trials for the experimental drug amycretin, designed to combat obesity and overweight conditions. The trials demonstrated that participants shed up to 24% of their body weight, paving the way for late-stage studies scheduled to commence next year.
Presented at the American Diabetes Association's annual meeting, the results indicated that the drug's side effects were primarily gastrointestinal, aligning with those seen in recent weight loss treatments. Amycretin acts through a dual mechanism by mimicking the gut hormone GLP-1 and targeting hunger-suppressing hormone receptors, achieving substantial weight reduction.
The upcoming Phase 3 program, slated to begin in 2026, will run "for a couple of years," with regulatory review anticipated to follow. Notably, oral administration trials also report significant weight loss, underscoring amycretin's potential in the evolving landscape of obesity management.
(With inputs from agencies.)
Google News